The 5th Inflammasome Therapeutics Summit returned to Boston and united industry pioneers at a critical time as clinical readouts are expected, and a wave of new collaborations hit the headlines.

As we focused on targeting beyond NLRP3 for treating inflammation, this event was your chance to join forces with like-minded individuals who prioritize inflammasome therapeutics.

Together, we addressed important aspects including discovery science and mechanisms, overcoming biomarker challenges such as measuring target engagement, disease selection, and making progress in developing preclinical models.

This was the largest gathering of inflammasome biopharma experts and pioneers set to advance inflammasome inhibitors and activators from the pipeline to in-human efficacy.

Industry super giants included NodThera, Zydus Therapeutics, Novartis, Roche, Ventus, AC Immune, and more, this was your chance to join forces with 100+ inflammasome pioneers for interactive discussions.